BUZZ - Henry Schein shares fall after appointing new Chief Financial Officer
路透社2026/10/08 11:47October 8 - ** Shares of dental products distributor Henry Schein (HSIC.O) dropped 2% to $82 in pre-market trading. ** Ronald South, who has served as CFO for the past four years, will transition to Senior Advisor. ** Emmanuel Caprais will take over as CFO, officially assuming the role on November 4. ** Caprais was previously the Chief Financial Officer of global industrial manufacturer ITT. ** This leadership change comes about seven months after Frederick Lowery succeeded Stanley Bergman as CEO; Bergman had led the company for 35 years. ** Among 18 brokers, 9 rate the stock as “buy” or above, 8 as “hold”, and 1 as “sell”; the median target price is $96—data compiled by LSEG. ** As of the previous trading day's close, the stock has risen 10.69% year-to-date.
October 8 - ** Shares of dental product distributor Henry Schein (HSIC.O) fell 2% in pre-market trading to $82
** Ronald South, who has served as chief financial officer for the past four years, will move to the role of senior advisor
** Emmanuel Caprais will take over as chief financial officer, officially assuming the role on November 4
** Caprais previously served as chief financial officer of global industrial manufacturer ITT
** The personnel changes come about seven months after Frederick Lowery replaced Stanley Bergman as chief executive officer; Bergman had led the company for 35 years
** Of 18 brokerages, nine rate the stock as "buy" or higher, eight as "hold", and one as "sell"; the median price target is $96—data compiled by LSEG
** As of the close of the previous trading day, the stock is up 10.69% year to date
(To assist non-native English speakers, Reuters provides automated translation of its reports into several other languages. Because automated translation may contain errors or fail to provide needed context, Reuters does not guarantee the accuracy of automated translations and provides them solely for reader convenience. Reuters accepts no responsibility for any loss or damage resulting from use of this automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
